Form 4: West Pharmaceutical Services Director Haugen Acquires Phantom Stock Units
SEC Form 4 Filing
Director Janet Brutschea Haugen acquired phantom stock units in West Pharmaceutical Services, to be settled upon termination as a director.
Summary
- On March 31, 2025, Janet Brutschea Haugen, a director of West Pharmaceutical Services Inc., acquired 56 phantom stock units.
- These units will be settled by delivery of common stock upon Haugen's termination as a director.
- The price of the derivative security is $223.88.
- Following the transaction, Haugen directly owns 56 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and insider alignment with company performance.
Future Outlook
The phantom stock units will be settled by delivery of shares of stock upon the reporting person's termination as a director.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of phantom stock units aligns the director's interests with those of the shareholders, as the value of the units is tied to the company's stock performance.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of transaction: Janet Haugen acquired phantom stock units. |
| 04/02/2025 | Date of signature for the report. |
Keywords
Form 4, Beneficial Ownership, Phantom Stock Units, West Pharmaceutical Services, Director, Haugen, WST
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.